Basal-like Phenotype Identifies Immunotherapy-Responsive Subset of HR+/HER2- Breast Cancer with Aggressive Clinical Behavior
Simple Summary HR+/HER2- breast cancer represents 70% of all breast cancers but has shown limited benefit from immunotherapy, with pathological complete response (pCR) rates of only 24–30% compared to 58–66% in triple-negative breast cancer (TNBC). This resistance has been considered an immutable biological characteris...